- Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
- Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
- Quince Therapeutics Launches Scientific Advisory Board
- Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
- Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Tuesday, Quince Therapeutics Inc (QNCX:NSQ) closed at 0.92, 9.52% above its 52-week low of 0.84, set on Nov 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.96 |
---|---|
High | 0.99 |
Low | 0.904 |
Bid | 0.91 |
Offer | 0.9693 |
Previous close | 0.96 |
Average volume | 76.51k |
---|---|
Shares outstanding | 43.22m |
Free float | 35.84m |
P/E (TTM) | -- |
Market cap | 41.49m USD |
EPS (TTM) | -0.8424 USD |
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼